Robin Swartz Sells 3,087 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 3,087 shares of the business’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $5.09, for a total transaction of $15,712.83. Following the sale, the chief operating officer now owns 109,241 shares in the company, valued at $556,036.69. The trade was a 2.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Robin Swartz also recently made the following trade(s):

• On Monday, December 23rd, Robin Swartz sold 6,500 shares of Voyager Therapeutics stock. The shares were sold at an average price of $5.65, for a total value of $36,725.00.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $5.06 on Friday. The company’s fifty day moving average price is $5.95 and its two-hundred day moving average price is $6.74. Voyager Therapeutics, Inc. has a one year low of $4.99 and a one year high of $10.66. The company has a market capitalization of $276.43 million, a price-to-earnings ratio of 7.13 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the prior year, the firm earned ($0.59) EPS. As a group, sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Wall Street Analyst Weigh In

VYGR has been the subject of a number of research analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Citigroup began coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. Finally, Leerink Partners initiated coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price for the company. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $15.97.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in VYGR. Armistice Capital LLC raised its stake in shares of Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after acquiring an additional 528,000 shares during the last quarter. Great Point Partners LLC bought a new position in Voyager Therapeutics in the 2nd quarter worth approximately $12,668,000. Geode Capital Management LLC lifted its holdings in Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after buying an additional 6,740 shares in the last quarter. Erste Asset Management GmbH bought a new position in Voyager Therapeutics in the 3rd quarter valued at $6,192,000. Finally, American Century Companies Inc. increased its stake in shares of Voyager Therapeutics by 32.4% in the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock valued at $8,063,000 after buying an additional 249,659 shares during the period. 48.03% of the stock is owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.